346 results on '"A. Barletta"'
Search Results
2. MP31-01 OPTIMIZING DETECTION AND PREDICTION OF PROSTATE CANCER AFTER POSITIVE MRI AND NEGATIVE BIOPSIES
3. PD19-10 PSMA RADIO-GUIDED SURGERY TO DETECT NODAL METASTASES IN PROSTATE CANCER PATIENTS UNDERGOING ROBOT-ASSISTED RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTION: UPDATED RESULTS OF A PLANNED INTERIM ANALYSIS OF A PROSPECTIVE PHASE 2 STUDY
4. MP52-17 RADICAL PROSTATECTOMY FOR NON-METASTATIC PROSTATE CANCER IN RENAL TRANSPLANT RECIPIENTS: OUTCOMES FROM A LARGE CONTEMPORARY COHORT AND MATCHED-PAIRED ANALYSIS WITH NON-TRANSPLANTED PATIENTS
5. PD61-03 EXTERNAL VALIDATION OF THE AVAILABLE NOMOGRAMS FOR THE IDENTIFICATION OF CANDIDATES FOR a STAGING EXTENDED PELVIC LYMPH NODE DISSECTION AT THE TIME OF RADICAL PROSTATECTOMY IN PROSTATE CANCER PATIENTS PREOPERATIVELY STAGED WITH PSMA PET
6. MP14-10 IDENTIFYING THE OPTIMAL CANDIDATE FOR CONCOMITANT ANDROGEN-DEPRIVATION THERAPY AMONG PATIENTS RECEIVING METASTASIS-DIRECTED THERAPY FOR POSITIVE PSMA PET AND PRIMARY OR SECONDARY BIOCHEMICAL RECURRENCE FROM PROSTATE CANCER
7. PD57-10 AGE-DEPENDENT EFFECT OF EARLY SALVAGE RADIOTHERAPY FOR BIOCHEMICAL RECURRENCE IN PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY
8. PD23-07 PROGNOSTIC SIGNIFICANCE OF LYMPH NODE COUNT IN SURGICALLY TREATED PATIENTS WITH T 2-4 STAGE NON-METASTATIC ADRENOCORTICAL CARCINOMA
9. PD57-09 ADJUVANT OR EARLY SALVAGE RADIOTHERAPY IN NODE POSITIVE PROSTATE CANCER PATIENTS: DEVELOPMENT OF A NOVEL RISK SCORE TO IDENTIFY THE OPTIMAL CANDIDATE FOR EARLY INTENSIFICATION APPROACHES BASED ON A LARGE, MULTI-INSTITUTIONAL SERIES
10. MP01-01 INCREMENTAL DOSE-RESPONSE EFFECT OF AGE ON MORTALITY IN NON-SEMINOMA TESTIS CANCER PATIENTS
11. MP14-11 THE ADDED VALUE OF CONCOMITANT WHOLE-PELVIS SALVAGE RADIATION THERAPY IN OLIGO-RECURRENT PROSTATE CANCER PATIENTS TREATED WITH METASTASIS-DIRECTED THERAPY FOR DISTANT POSITIVE UPTAKES AT PSMA PET
12. MP14-01 RATES AND PREDICTORS OF FALSE NODE-POSITIVE PSMA-PET IN PATIENTS TREATED WITH RADICAL PROSTATECTOMY AND EXTEND PELVIC LYMPH-NODE DISSECTION: RESULTS FROM A LARGE, MULTI-INSTITUTIONAL DATABASE
13. PD09-03 ASSESSING EPIGENETIC FEATURES ASSOCIATED WITH LYMPH NODE METASTASES IN PROSTATE CANCER
14. MP19-19 THE IMPACT OF MULTIPLE LESIONS IN PROSTATE MRI-INSIGHTS FROM THE YAU PROSTATE CANCER GROUP
15. MP19-15 THE SIGNIFICANT ADDED VALUE OF CONCOMITANT SYSTEMATIC PROSTATE BIOPSIES IN ADDITION TO TARGETED SAMPLING IN PATIENTS WITH PREVIOUS NEGATIVE BIOPSIES. IMPLICATIONS FOR ACCURATE STAGING PREDICTIONS FROM A LARGE MULTI-INSTITUTIONAL SERIES
16. MP31-19 “THE MORE YOU SEE THE MORE YOU MISS” PSMA PET/CT IS STILL AFFECTED BY A SUBSTANTIAL RISK OF UNDERESTIMATION IN PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY
17. MP37-20 THE EFFECT OF PENILE REHABILITATION AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY ON URINARY CONTINENCE AND ERECTILE FUNCTION RECOVERY. RESULTS FROM a HIGH-VOLUME, SINGLE-SURGEON SERIES
18. MP14-18 ONCOLOGICAL OUTCOMES OF PN1 PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY: DOES MOLECULAR IMAGING HAVE A PROGNOSTIC IMPACT? RESULTS OF A LARGE, MULTI-INSTITUTIONAL SERIES
19. PD61-04 LONG-TERM ONCOLOGICAL OUTCOMES OF SURGICALLY MANAGED VERY HIGH-RISK PROSTATE CANCER PATIENTS ACCORDING TO THE STAMPEDE TRIAL DEFINITION: IMPLICATIONS FOR THE SELECTION OF CANDIDATES FOR CLINICAL TRIALS
20. Management of Heat-Related Illness and Injury in the ICU: A Concise Definitive Review
21. Concise Definitive Review: In-Hospital Violence and Its Impact on Critical Care Practitioners
22. 917: ICU CLINICAL PHARMACIST-TO-PATIENT RATIOS: A PROSPECTIVE, MULTICENTER TIME-MOTION STUDY
23. Empiric Carbapenem Therapy for Sepsis: Are We Winning the Battle at the Expense of the War?*
24. PEComa of the Adrenal Gland
25. The role of nuclear medicine tracers for prostate cancer surgery: from preoperative to intraoperative setting
26. Prophylactic acid suppression and enteral nutrition
27. NUTM1-rearranged Carcinoma of the Thyroid
28. MP50-06 SURVIVAL OF TESTICULAR PURE TERATOMA VS. MIXED GERM CELL TUMOR PATIENTS ACROSS ALL STAGES
29. MP61-12 WHICH MEN WITH CN1 PROSTATE CANCER AT PSMA PET/CT REPRESENT THE IDEAL CANDIDATE TO RADICAL PROSTATECTOMY? DEVELOPMENT OF A NOVEL RISK STRATIFICATION TOOL FOR INDIVIDUALIZED APPROACHES BASED ON A LARGE, MULTI-INSTITUTIONAL SERIES
30. PD10-09 A NOVEL MODEL INTEGRATING CLINICAL, MP-MRI, AND EPIGENOMIC FEATURES TO PREDICT LYMPH NODE INVASION IN PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY AND PELVIC LYMPH NODE DISSECTION
31. MP67-06 OUTCOMES OF PROSTATE CANCER PATIENTS WITH SEMINAL VESICLE INVASION AT MULTIPARAMETRIC MRI MANAGED WITH RADICAL PROSTATECTOMY. DO ALL PATIENTS REALLY NEED A MULTI-MODAL APPROACH?
32. MP40-14 ARE EAU RISK GROUPS RELIABLE IN THE STRATIFICATION OF MEN WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY AND RESTAGED WITH PSMA-PET?
33. MP67-03 IDENTIFYING THE OPTIMAL CANDIDATES FOR A SUPER-EXTENDED STAGING PELVIC LYMPH-NODE DISSECTION IN PROSTATE CANCER PATIENTS TREATED IN THE PET-PSMA ERA. RESULTS FROM A MULTI-INSTITUTIONAL SERIES
34. MP11-11 TAILORING THE OPTIMAL USE OF ANDROGEN-DEPRIVATION THERAPY CONCOMITANT TO POST-OPERATIVE RADIOTHERAPY AMONG MEN WITH PN1 PROSTATE CANCER. LONG-TERM RESULTS OF A LARGE, SINGLE INSTITUTION SERIES
35. PD16-05 A SYSTEMATIC REVIEW TO EVALUATE PATIENT-REPORTED OUTCOMES MEASURES (PROMS) FOR METASTATIC PROSTATE CANCER ACCORDING TO THE COSMIN METHODOLOGY: A PIONEER WP2 PROJECT
36. MP61-14 PSMA RADIO-GUIDED SURGERY TO DETECT NODAL METASTASES IN PROSTATE CANCER PATIENTS UNDERGOING ROBOT-ASSISTED RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTION: UPDATED RESULTS OF PLANNED INTERIM ANALYSES OF A PROSPECTIVE PHASE 2 STUDY
37. MP67-04 VALIDATION OF NOVEL PREOPERATIVE RISK CATEGORIES ON THE PREDICTION OF CLINICAL RECURRENCE IN PATIENTS CANDIDATE FOR RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER. RESULTS OF A LARGE, MULTI-INSTITUTIONAL SERIES
38. PD10-08 THE PROGNOSTIC IMPACT OF PREOPERATIVE PSMA-PET ON EARLY ONCOLOGICAL OUTCOMES IN PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY: RESULTS OF A MULTI-CENTER ANALYSIS
39. MP67-07 CAN WE PREDICT THE SITE OF POSITIVE SURGICAL MARGINS (PSM) BASED ON THE SITE OF THE INDEX LESION AT MULTIPARAMETRIC MRI? A TOPOGRAPHIC SINGLE CENTER STUDY
40. MP67-03 IDENTIFYING THE OPTIMAL CANDIDATES FOR A SUPER-EXTENDED STAGING PELVIC LYMPH-NODE DISSECTION IN PROSTATE CANCER PATIENTS TREATED IN THE PET-PSMA ERA. RESULTS FROM A MULTI-INSTITUTIONAL SERIES
41. MP67-06 OUTCOMES OF PROSTATE CANCER PATIENTS WITH SEMINAL VESICLE INVASION AT MULTIPARAMETRIC MRI MANAGED WITH RADICAL PROSTATECTOMY. DO ALL PATIENTS REALLY NEED A MULTI-MODAL APPROACH?
42. PD10-09 A NOVEL MODEL INTEGRATING CLINICAL, MP-MRI, AND EPIGENOMIC FEATURES TO PREDICT LYMPH NODE INVASION IN PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY AND PELVIC LYMPH NODE DISSECTION
43. MP67-04 VALIDATION OF NOVEL PREOPERATIVE RISK CATEGORIES ON THE PREDICTION OF CLINICAL RECURRENCE IN PATIENTS CANDIDATE FOR RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER. RESULTS OF A LARGE, MULTI-INSTITUTIONAL SERIES
44. MP40-14 ARE EAU RISK GROUPS RELIABLE IN THE STRATIFICATION OF MEN WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY AND RESTAGED WITH PSMA-PET?
45. MP11-11 TAILORING THE OPTIMAL USE OF ANDROGEN-DEPRIVATION THERAPY CONCOMITANT TO POST-OPERATIVE RADIOTHERAPY AMONG MEN WITH PN1 PROSTATE CANCER. LONG-TERM RESULTS OF A LARGE, SINGLE INSTITUTION SERIES
46. MP67-07 CAN WE PREDICT THE SITE OF POSITIVE SURGICAL MARGINS (PSM) BASED ON THE SITE OF THE INDEX LESION AT MULTIPARAMETRIC MRI? A TOPOGRAPHIC SINGLE CENTER STUDY
47. PD10-08 THE PROGNOSTIC IMPACT OF PREOPERATIVE PSMA-PET ON EARLY ONCOLOGICAL OUTCOMES IN PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY: RESULTS OF A MULTI-CENTER ANALYSIS
48. MP61-12 WHICH MEN WITH CN1 PROSTATE CANCER AT PSMA PET/CT REPRESENT THE IDEAL CANDIDATE TO RADICAL PROSTATECTOMY? DEVELOPMENT OF A NOVEL RISK STRATIFICATION TOOL FOR INDIVIDUALIZED APPROACHES BASED ON A LARGE, MULTI-INSTITUTIONAL SERIES
49. MP50-06 SURVIVAL OF TESTICULAR PURE TERATOMA VS. MIXED GERM CELL TUMOR PATIENTS ACROSS ALL STAGES
50. PD16-05 A SYSTEMATIC REVIEW TO EVALUATE PATIENT-REPORTED OUTCOMES MEASURES (PROMS) FOR METASTATIC PROSTATE CANCER ACCORDING TO THE COSMIN METHODOLOGY: A PIONEER WP2 PROJECT
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.